-DOCSTART-	O

Title	O
:	O
Early	O
use	O
of	O
nitazoxanide	B-I
in	O
mild	O
COVID	O
-	O
19	O
disease	O
:	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
adult	B-P
patients	I-P
presenting	I-P
up	I-P
to	I-P
3	I-P
days	I-P
after	I-P
onset	I-P
of	I-P
coronavirus	I-P
disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
symptoms	I-P
(	I-P
dry	I-P
cough	I-P
,	I-P
fever	I-P
and	I-P
/	I-P
or	I-P
fatigue	I-P
)	I-P
were	O
enrolled	O
.	O

After	O
confirmation	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
using	O
reverse	O
transcriptase	O
PCR	O
on	O
a	O
nasopharyngeal	O
swab	O
,	O
patients	O
were	O
randomised	O
1	O
:	O
1	O
to	O
receive	O
either	O
nitazoxanide	B-I
(	O
500	O
mg	O
)	O
or	O
placebo	B-C
,	O
three	O
times	O
daily	O
,	O
for	O
5	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
complete	B-O
resolution	I-O
of	I-O
symptoms	I-O
.	O

Secondary	O
outcomes	O
were	O
viral	B-O
load	I-O
,	O
laboratory	B-O
tests	I-O
,	O
serum	B-O
biomarkers	I-O
of	I-O
inflammation	I-O
and	O
hospitalisation	B-O
rate	I-O
.	O

Adverse	B-O
events	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
COvid	O
-	O
19	O
and	O
high	B-I
-	I-I
dose	I-I
VITamin	I-I
D	I-I
supplementation	I-I
TRIAL	O
in	O
high	B-P
-	I-P
risk	I-P
older	I-P
patients	I-P
(	O
COVIT	O
-	O
TRIAL	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	O
COVIT	O
-	O
TRIAL	O
study	O
is	O
an	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
randomized	O
controlled	O
superiority	O
trial	O
.	O

Patients	B-P
aged	I-P
?	I-P
65	I-P
years	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
diagnosed	I-P
within	I-P
the	I-P
preceding	I-P
3	I-P
days	I-P
with	I-P
RT	I-P
-	I-P
PCR	I-P
and	I-P
/	I-P
or	I-P
chest	I-P
CT	I-P
scan	I-P
)	I-P
and	I-P
at	I-P
least	I-P
one	I-P
worsening	I-P
risk	I-P
factor	I-P
at	I-P
the	I-P
time	I-P
of	I-P
inclusion	I-P
(	I-P
i	I-P
.	I-P
e	I-P
.	I-P
,	I-P
age	I-P
?	I-P
75	I-P
years	I-P
,	I-P
or	I-P
SpO2	I-P
?	I-P
94	I-P
%	I-P
in	I-P
room	I-P
air	I-P
,	I-P
or	I-P
PaO2	I-P
/	I-P
FiO2	I-P
?	I-P
300	I-P
mmHg	I-P
)	I-P
,	I-P
having	I-P
no	I-P
contraindications	I-P
to	I-P
vitamin	I-P
D	I-P
supplementation	I-P
,	I-P
and	I-P
having	I-P
received	I-P
no	I-P
vitamin	I-P
D	I-P
supplementation	I-P
>	I-P
800	I-P
IU	I-P
/	I-P
day	I-P
during	I-P
the	I-P
preceding	I-P
month	I-P
are	O
recruited	O
.	O

Participants	O
are	O
randomized	O
either	O
to	O
high	B-I
-	I-I
dose	I-I
cholecalciferol	I-I
(	O
two	O
200	O
,	O
000	O
IU	O
drinking	O
vials	O
at	O
once	O
on	O
the	O
day	O
of	O
inclusion	O
)	O
or	O
to	O
standard	B-C
-	I-C
dose	I-C
cholecalciferol	I-C
(	O
one	O
50	O
,	O
000	O
IU	O
drinking	O
vial	O
on	O
the	O
day	O
of	O
inclusion	O
)	O
.	O

Two	B-P
hundred	I-P
sixty	I-P
participants	I-P
are	O
recruited	O
and	O
followed	O
up	O
for	O
28	O
days	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
within	O
14	O
days	O
of	O
inclusion	O
.	O

Secondary	O
outcomes	O
are	O
the	O
score	O
changes	O
on	O
the	B-O
World	I-O
Health	I-O
Organization	I-O
Ordinal	I-O
Scale	I-O
for	I-O
Clinical	I-O
Improvement	I-O
(	I-O
OSCI	I-O
)	I-O
scale	I-O
for	I-O
COVID	I-O
-	I-O
19	I-O
,	O
and	O
the	O
between	O
-	O
group	O
comparison	O
of	O
safety	B-O
.	O

These	O
outcomes	O
are	O
assessed	O
at	O
baseline	O
,	O
day	O
14	O
,	O
and	O
day	O
28	O
,	O
together	O
with	O
the	B-O
serum	I-O
concentrations	I-O
of	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
,	O
creatinine	B-O
,	O
calcium	B-O
,	O
and	O
albumin	B-O
at	O
baseline	O
and	O
day	O
7	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
combined	O
with	O
favipiravir	B-I
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
A	O
multicenter	O
trial	O
in	O
a	O
small	O
sample	O
size	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
trial	O
in	O
adults	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
3:1:1	O
)	O
to	O
a	B-I
14	I-I
-	I-I
day	I-I
combination	I-I
of	I-I
favipiravir	I-I
combined	O
with	O
tocilizumab	B-I
(	O
combination	O
group	O
)	O
,	O
favipiravir	B-I
,	O
and	O
tocilizumab	B-I
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
lung	I-O
lesion	I-O
remission	I-O
rate	I-O
(	O
lung	B-O
CT	I-O
examination	I-O
indicated	I-O
absorption	I-O
of	I-O
lung	I-O
inflammation	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Nasopharyngeal	O
swab	O
-	O
induced	O
pain	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
screening	O
:	O
A	O
randomised	O
controlled	O
trial	O
of	O
conventional	O
and	O
self	O
-	O
swabbing	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
in	O
Clermont	O
-	O
Ferrand	O
medical	O
school	O
(	O
France	O
)	O
.	O

Overall	O
,	O
190	B-P
students	I-P
were	O
randomised	O
into	O
two	O
groups	O
and	O
experienced	O
either	O
self	B-I
-	I-I
or	O
conventional	B-C
-	I-C
swabbing	I-C
.	O

Each	O
subject	O
had	O
to	O
rate	O
pain	B-O
,	O
discomfort	B-O
and	O
acceptability	B-O
of	I-O
such	I-O
swabbing	I-O
on	O
a	B-O
0	I-O
-	I-O
10	I-O
numeric	I-O
rating	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
moxibustion	B-I
on	O
clinical	O
symptoms	O
,	O
peripheral	O
inflammatory	O
indexes	O
and	O
T	O
lymphocyte	O
subsets	O
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
95	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
divided	O
into	O
a	B-I
moxibustion	I-I
group	O
(	O
45	O
cases	O
)	O
and	O
a	O
basic	O
treatment	O
group	O
(	O
50	O
cases	O
)	O
.	O

The	O
routine	O
treatment	O
of	O
western	O
medicine	O
was	O
applied	O
in	O
the	O
patients	O
of	O
both	O
groups	O
.	O

In	O
the	B-I
moxibustion	I-I
group	O
,	O
on	O
the	O
base	O
of	O
the	O
treatment	O
of	O
western	O
medicine	O
,	O
moxibustion	B-I
was	O
applied	O
to	O
Dazhui	O
(	O
GV	O
14	O
)	O
,	O
Feishu	O
(	O
BL	O
13	O
)	O
,	O
Qihai	O
(	O
CV	O
6	O
)	O
and	O
Zusanli	O
(	O
ST	O
36	O
)	O
,	O
once	O
daily	O
and	O
consecutively	O
for	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
treatment	O
courses	O
,	O
clinical	B-O
symptom	I-O
scores	I-O
for	I-O
cough	I-O
,	O
asthmatic	B-O
breathing	I-O
,	O
chest	B-O
oppression	I-O
and	O
short	B-O
breath	I-O
,	O
as	O
well	O
as	O
their	B-O
remission	I-O
rates	I-O
were	O
compared	O
between	O
the	O
two	O
groups	O
before	O
and	O
after	O
treatment	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	B-O
white	I-O
blood	I-O
cell	I-O
(	I-O
WBC	I-O
)	I-O
count	I-O
,	O
the	B-O
levels	I-O
of	I-O
c	I-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
CRP	I-O
)	I-O
and	O
interleukin	B-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
and	O
the	B-O
absolute	I-O
number	I-O
of	I-O
T	I-O
lymphocyte	I-O
subsets	I-O
,	O
i	O
.	O
e	O
.	O
,	O
and	O
of	O
the	B-O
peripheral	I-O
blood	I-O
were	O
compared	O
in	O
the	O
patients	O
between	O
the	O
two	O
groups	O
.	O

The	O
principal	O
component	O
analysis	O
was	O
adopted	O
to	O
analyze	O
the	O
common	O
data	O
extracted	O
from	O
the	O
above	O
10	O
clinical	O
indexes	O
variables	O
and	O
comprehensively	O
evaluate	O
the	O
differences	O
in	O
the	O
therapeutic	O
effect	O
of	O
two	O
regimens	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Discontinuing	B-I
vs	O
Continuing	B-I
Angiotensin	I-I
-	I-I
Converting	I-I
Enzyme	I-I
Inhibitors	I-I
and	O
Angiotensin	B-I
II	I-I
Receptor	I-I
Blockers	I-I
on	O
Days	O
Alive	O
and	O
Out	O
of	O
the	O
Hospital	O
in	O
Patients	B-P
Admitted	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
clinical	O
trial	O
of	O
659	B-P
patients	I-P
hospitalized	I-P
in	I-P
Brazil	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
taking	I-P
ACEIs	I-P
or	I-P
ARBs	I-P
prior	I-P
to	I-P
hospitalization	I-P
(	I-P
enrolled	I-P
:	I-P
April	I-P
9	I-P
-	I-P
June	I-P
26	I-P
,	I-P
2020	I-P
;	I-P
final	I-P
follow	I-P
-	I-P
up	I-P
:	I-P
July	I-P
26	I-P
,	I-P
2020	I-P
)	I-P
.	O

Discontinuation	B-I
(	O
n	O
=	O
334	O
)	O
or	O
continuation	B-I
(	I-I
n	I-I
=	I-I
325	I-I
)	I-I
of	I-I
ACEIs	I-I
or	O
ARBs	B-I
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
number	I-O
of	I-O
days	I-O
alive	I-O
and	O
out	B-O
of	I-O
the	I-O
hospital	I-O
through	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
death	B-O
,	O
cardiovascular	B-O
death	I-O
,	O
and	O
COVID	B-O
-	I-O
19	I-O
progression	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Bamlanivimab	B-I
as	O
Monotherapy	O
or	O
in	O
Combination	O
With	O
Etesevimab	B-I
on	O
Viral	O
Load	O
in	O
Patients	B-P
With	I-P
Mild	I-P
to	I-P
Moderate	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
The	O
BLAZE	O
-	O
1	O
study	O
is	O
a	O
randomized	O
phase	O
2	O
/	O
3	O
trial	O
at	O
49	O
US	O
centers	O
including	O
ambulatory	B-P
patients	I-P
(	I-P
N	I-P
=	I-P
613	I-P
)	I-P
who	I-P
tested	I-P
positive	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
and	I-P
had	I-P
1	I-P
or	I-P
more	I-P
mild	I-P
to	I-P
moderate	I-P
symptoms	I-P
.	O

Patients	O
who	O
received	O
bamlanivimab	B-I
monotherapy	O
or	O
placebo	B-C
were	O
enrolled	O
first	O
(	O
June	O
17	O
-	O
August	O
21	O
,	O
2020	O
)	O
followed	O
by	O
patients	O
who	O
received	O
bamlanivimab	B-I
and	O
etesevimab	B-I
or	O
placebo	B-C
(	O
August	O
22	O
-	O
September	O
3	O
)	O
.	O

These	O
are	O
the	O
final	O
analyses	O
and	O
represent	O
findings	O
through	O
October	O
6	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
a	B-I
single	I-I
infusion	I-I
of	I-I
bamlanivimab	I-I
(	O
700	O
mg	O
[	O
n	O
=	O
101	O
]	O
,	O
2800	O
mg	O
[	O
n	O
=	O
107	O
]	O
,	O
or	O
7000	O
mg	O
[	O
n	O
=	O
101	O
]	O
)	O
,	O
the	B-I
combination	I-I
treatment	I-I
(	O
2800	B-I
mg	I-I
of	I-I
bamlanivimab	I-I
and	O
2800	B-I
mg	I-I
of	I-I
etesevimab	I-I
[	O
n	O
=	O
112	O
]	O
)	O
,	O
or	O
placebo	B-C
(	O
n	O
=	O
156	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
change	O
in	O
SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
log	I-O
viral	I-O
load	I-O
at	O
day	O
11	O
(	O
4	O
days	O
)	O
.	O

Nine	O
prespecified	O
secondary	O
outcome	O
measures	O
were	O
evaluated	O
with	O
comparisons	O
between	O
each	O
treatment	O
group	O
and	O
placebo	B-C
,	O
and	O
included	O
3	B-O
other	I-O
measures	I-O
of	I-O
viral	I-O
load	I-O
,	O
5	B-O
on	I-O
symptoms	I-O
,	O
and	O
1	B-O
measure	I-O
of	I-O
clinical	I-O
outcome	I-O
(	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
a	I-O
COVID	I-O
-	I-O
19	I-O
-	I-O
related	I-O
hospitalization	I-O
,	O
an	B-O
emergency	I-O
department	I-O
[	I-O
ED	I-O
]	I-O
visit	I-O
,	O
or	O
death	B-O
at	O
day	O
29	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	O
Use	O
of	O
Corticosteroid	B-I
May	O
Prolong	O
SARS	O
-	O
CoV	O
-	O
2	O
Shedding	O
in	O
Non	B-P
-	I-P
Intensive	I-P
Care	I-P
Unit	I-P
Patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
Pneumonia	I-P
:	O
A	O
Multicenter	O
,	O
Single	O
-	O
Blind	O
,	O
Randomized	O
Control	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
prospective	O
,	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
control	O
trial	O
.	O

Adult	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
general	I-P
ward	I-P
were	O
randomly	O
assigned	O
to	O
either	O
receive	O
methylprednisolone	B-I
or	O
not	B-C
for	O
7	O
days	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
incidence	I-O
of	I-O
clinical	I-O
deterioration	I-O
14	O
days	O
after	O
randomization	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
anakinra	B-I
versus	O
usual	B-C
care	I-C
in	O
adults	B-P
in	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
pneumonia	I-P
(	O
CORIMUNO	O
-	O
ANA	O
-	O
1	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
Bayesian	O
randomised	O
clinical	O
trial	O
(	O
CORIMUNO	O
-	O
ANA	O
-	O
1	O
)	O
,	O
nested	O
within	O
the	O
CORIMUNO	O
-	O
19	O
cohort	O
,	O
we	O
recruited	O
patients	B-P
from	I-P
16	I-P
University	I-P
hospitals	I-P
in	I-P
France	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
,	I-P
severe	I-P
acute	I-P
respiratory	I-P
syndrome	I-P
coronavirus	I-P
2	I-P
infection	I-P
confirmed	I-P
by	I-P
real	I-P
-	I-P
time	I-P
RT	I-P
-	I-P
PCR	I-P
,	I-P
requiring	I-P
at	I-P
least	I-P
3	I-P
L	I-P
/	I-P
min	I-P
of	I-P
oxygen	I-P
by	I-P
mask	I-P
or	I-P
nasal	I-P
cannula	I-P
but	I-P
without	I-P
ventilation	I-P
assistance	I-P
,	I-P
a	I-P
score	I-P
of	I-P
5	I-P
on	I-P
the	I-P
WHO	I-P
Clinical	I-P
Progression	I-P
Scale	I-P
(	I-P
WHO	I-P
-	I-P
CPS	I-P
)	I-P
,	I-P
and	I-P
a	I-P
C	I-P
-	I-P
reactive	I-P

protein	I-P
serum	I-P
concentration	I-P
of	I-P
more	I-P
than	I-P
25	I-P
mg	I-P
/	I-P
L	I-P
not	I-P
requiring	I-P
admission	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
at	I-P
admission	I-P
to	I-P
hospital	I-P
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
using	O
a	O
web	O
-	O
based	O
secure	O
centralised	O
system	O
,	O
stratified	O
by	O
centre	O
and	O
blocked	O
with	O
varying	O
block	O
sizes	O
(	O
randomly	O
of	O
size	O
two	O
or	O
four	O
)	O
,	O
to	O
either	O
usual	B-I
care	I-I
plus	O
anakinra	B-I
(	O
200	O
mg	O
twice	O
a	O
day	O
on	O
days	O
1	O
-	O
3	O
,	O
100	O
mg	O
twice	O
on	O
day	O
4	O
,	O
100	O
mg	O
once	O
on	O
day	O
5	O
)	O
or	O
usual	B-C
care	I-C
alone	I-C
.	O

Usual	B-C
care	I-C
was	O
provided	O
at	O
the	O
discretion	O
of	O
the	O
site	O
clinicians	O
.	O

The	O
two	O
coprimary	O
outcomes	O
were	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
had	I-O
died	I-O
or	O
needed	B-O
non	I-O
-	I-O
invasive	I-O
or	O
mechanical	B-O
ventilation	I-O
by	O
day	O
4	O
(	O
ie	O
,	O
a	O
score	O
of	O
>	O
5	O
on	O
the	O
WHO	O
-	O
CPS	O
)	O
and	O
survival	B-O
without	I-O
need	I-O
for	I-O
mechanical	I-O
or	O
non	B-O
-	I-O
invasive	I-O
ventilation	I-O
(	O
including	O
high	O
-	O
flow	O
oxygen	O
)	O
at	O
day	O
14	O
.	O

All	O
analyses	O
were	O
done	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04341584	O
,	O
and	O
is	O
now	O
closed	O
to	O
accrual	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
sofosbuvir	B-I
/	O
ledipasvir	B-I
in	O
treatment	O
of	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
;	O
A	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Among	O
an	O
open	O
-	O
label	O
randomized	O
clinical	O
trial	O
,	O
82	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderated	I-P
COVID	I-P
-	I-P
19	I-P
were	O
assigned	O
to	O
receive	O
either	O
SOF	B-I
/	O
LDP	B-I
400	O
/	O
100	O
mg	O
daily	O
plus	O
the	B-I
standard	I-I
of	I-I
care	I-I
(	O
SOF	B-I
/	O
LDP	B-I
group	O
,	O
n=42	O
)	O
or	O
the	B-C
standard	I-C
of	I-C
care	I-C
alone	I-C
(	O
control	O
group	O
,	O
n=40	O
)	O
for	O
10	O
days	O
.	O

Time	B-O
to	I-O
clinical	I-O
response	I-O
,	O
rate	B-O
of	I-O
clinical	I-O
response	I-O
,	O
duration	B-O
of	I-O
hospital	I-O
and	O
ICU	B-O
stay	I-O
and	O
14	B-O
-	I-O
day	I-O
mortality	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Methylprednisolone	B-I
in	O
adults	B-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
:	O
An	O
open	O
-	O
label	O
randomized	O
trial	O
(	O
GLUCOCOVID	O
)	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
multicentric	O
open	O
-	O
label	O
trial	O
of	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
who	I-P
were	I-P
aged	I-P
?	I-P
18	I-P
years	I-P
,	I-P
receiving	I-P
oxygen	I-P
without	I-P
mechanical	I-P
ventilation	I-P
,	I-P
and	I-P
with	I-P
evidence	I-P
of	I-P
systemic	I-P
inflammatory	I-P
response	I-P
who	O
were	O
assigned	O
to	O
standard	B-C
of	I-C
care	I-C
(	I-C
SOC	I-C
)	I-C
or	O
SOC	B-I
plus	O
intravenous	B-I
MP	I-I
(	O
40	O
mg	O
bid	O
for	O
3	O
days	O
followed	O
by	O
20	O
mg	O
bid	O
for	O
3	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
a	B-O
composite	I-O
of	I-O
death	I-O
,	O
admission	B-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
,	O
or	O
requirement	B-O
for	I-O
noninvasive	I-O
ventilation	I-O
.	O

Both	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
and	O
per	O
protocol	O
(	O
PP	O
)	O
analyses	O
were	O
performed	O
.	O

-DOCSTART-	O

Title	O
:	O
Azithromycin	B-I
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
RECOVERY	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
platform	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
(	O
Randomised	O
Evaluation	O
of	O
COVID	O
-	O
19	O
Therapy	O
[	O
RECOVERY	O
]	O
)	O
,	O
several	O
possible	O
treatments	O
were	O
compared	O
with	O
usual	O
care	O
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
in	I-P
the	I-P
UK	I-P
.	O

The	O
trial	O
is	O
underway	O
at	O
176	O
hospitals	O
in	O
the	O
UK	O
.	O

Eligible	O
and	O
consenting	O
patients	O
were	O
randomly	O
allocated	O
to	O
either	O
usual	B-C
standard	I-C
of	I-C
care	I-C
alone	I-C
or	O
usual	B-I
standard	I-I
of	I-I
care	I-I
plus	O
azithromycin	B-I
500	O
mg	O
once	O
per	O
day	O
by	O
mouth	O
or	O
intravenously	O
for	O
10	O
days	O
or	O
until	O
discharge	O
(	O
or	O
allocation	O
to	O
one	O
of	O
the	O
other	O
RECOVERY	O
treatment	O
groups	O
)	O
.	O

Patients	O
were	O
assigned	O
via	O
web	O
-	O
based	O
simple	O
(	O
unstratified	O
)	O
randomisation	O
with	O
allocation	O
concealment	O
and	O
were	O
twice	O
as	O
likely	O
to	O
be	O
randomly	O
assigned	O
to	O
usual	O
care	O
than	O
to	O
any	O
of	O
the	O
active	O
treatment	O
groups	O
.	O

Participants	O
and	O
local	O
study	O
staff	O
were	O
not	O
masked	O
to	O
the	O
allocated	O
treatment	O
,	O
but	O
all	O
others	O
involved	O
in	O
the	O
trial	O
were	O
masked	O
to	O
the	O
outcome	O
data	O
during	O
the	O
trial	O
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
all	I-O
-	I-O
cause	I-O
mortality	I-O
,	O
assessed	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
50189673	O
,	O
and	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04381936	O
.	O

-DOCSTART-	O

Title	O
:	O
Peginterferon	B-I
lambda	I-I
for	O
the	O
treatment	O
of	O
outpatients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
phase	O
2	O
,	O
placebo	O
-	O
controlled	O
randomised	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
outpatients	B-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
assigned	O
to	O
a	O
single	O
subcutaneous	O
injection	O
of	O
peginterferon	B-I
lambda	I-I
180	O
?g	O
or	O
placebo	B-C
within	O
7	O
days	O
of	O
symptom	O
onset	O
or	O
first	O
positive	O
swab	O
if	O
asymptomatic	O
.	O

Participants	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
using	O
a	O
computer	O
-	O
generated	O
randomisation	O
list	O
created	O
with	O
a	O
randomisation	O
schedule	O
in	O
blocks	O
of	O
four	O
.	O

At	O
the	O
time	O
of	O
administration	O
,	O
study	O
nurses	O
received	O
a	O
sealed	O
opaque	O
envelope	O
with	O
the	O
treatment	O
allocation	O
number	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
were	I-O
negative	I-O
for	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
(	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
)	I-O
RNA	I-O
on	O
day	O
7	O
after	O
the	O
injection	O
,	O
analysed	O
by	O
a	O
?2	O
test	O
following	O
an	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
.	O

Prespecified	O
analysis	O
of	O
the	O
primary	O
endpoint	O
,	O
adjusted	O
for	O
baseline	O
viral	B-O
load	I-O
,	O
using	O
bivariate	O
logistic	O
regression	O
was	O
done	O
.	O

The	O
trial	O
is	O
now	O
complete	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04354259	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
online	B-I
multimedia	I-I
psychoeducational	I-I
interventions	I-I
on	O
the	O
resilience	O
and	O
perceived	O
stress	O
of	O
hospitalized	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
pilot	O
cluster	O
randomized	O
parallel	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
pilot	O
cluster	O
randomized	O
parallel	O
-	O
controlled	O
trial	O
with	O
hospital	O
wards	O
as	O
the	O
units	O
of	O
randomization	O
.	O

Participants	O
in	O
this	O
fully	O
online	O
trial	O
were	O
50	B-P
consecutive	I-P
patients	I-P
who	I-P
were	I-P
hospitalized	I-P
in	I-P
2	I-P
hospitals	I-P
in	I-P
Shiraz	I-P
,	I-P
after	I-P
being	I-P
diagnosed	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Before	O
the	O
beginning	O
of	O
the	O
intervention	O
,	O
four	O
inpatient	O
wards	O
inside	O
two	O
of	O
the	O
hospitals	O
were	O
randomly	O
assigned	O
to	O
either	O
intervention	O
or	O
control	O
conditions	O
.	O

All	O
eligible	O
participants	O
in	O
the	O
wards	O
allocated	O
to	O
the	O
intervention	O
condition	O
received	O
online	B-I
multimedia	I-I
psychoeducational	I-I
interventions	I-I
during	O
the	O
2	O
weeks	O
,	O
whilst	O
the	O
patients	O
in	O
the	O
wards	O
allocated	O
to	O
the	O
control	O
condition	O
were	O
offered	O
the	O
opportunity	O
to	O
receive	O
telephone	B-C
-	I-C
based	I-C
psychological	I-C
counseling	I-C
if	O
needed	O
.	O

Psychoeducational	B-I
interventions	I-I
mainly	O
included	O
cognitive	B-I
-	I-I
behavioural	I-I
techniques	I-I
,	O
stress	B-I
management	I-I
techniques	I-I
,	O
mindfulness	B-I
-	I-I
based	I-I
stress	I-I
reduction	I-I
and	O
positive	B-I
psychotherapy	I-I
.	O

The	O
patients	O
were	O
assessed	O
regarding	O
resilience	B-O
and	O
perceived	B-O
stress	I-O
at	O
baseline	O
and	O
after	O
two	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
effectiveness	O
of	O
high	B-I
-	I-I
dose	I-I
vitamin	I-I
C	I-I
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomized	O
open	O
-	O
label	O
clinical	O
trial	O
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
and	O
controlled	O
trial	O
was	O
conducted	O
on	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
.	O

The	O
case	O
and	O
control	O
treatment	O
groups	O
each	O
consisted	O
of	O
30	O
patients	O
.	O

The	O
control	O
group	O
received	O
lopinavir	B-C
/	O
ritonavir	B-C
and	O
hydroxychloroquine	B-C
and	O
the	O
case	O
group	O
received	O
HDIVC	B-I
(	O
6	O
g	O
daily	O
)	O
added	O
to	O
the	O
same	O
regimen	O
.	O

